The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Walentowicz Sadlecka, Malgorzata ^a   Malkowski, Bogdan ^b   Walentowicz, Pawel ^a   Sadlecki, Pawel ^a   Marszalek, Andrzej ^a   Pietrzak, Tomasz ^b   Grabiec, Marek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Lukaszczyk Oncology Center of Bydgoszcz   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDOMETRIUM CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PET-CT SCANNER; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; RADICAL RESECTION; RECEIVER OPERATING CHARACTERISTIC; TUMOR INVASION; VERY ELDERLY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897884556     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/234813     Document Type: Article

References (26)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. Cancer Journal for Clinicians 2012 62 1 10 29 2-s2.0-84855792427 10.3322/caac.20138
2. Markowska J., Madry R., Zarys Ginekologii Onkologicznej 2012 2 Poznan Termedia
3. Bi F. F., Li D., Yang Q., Hypomethylation of ETS transcription factor binding sites and upregulation of PARP1 expression in endometrial cancer. BioMed Research International 2013 2013 5 946268 10.1155/2013/946268
4. Dong P., Kaneuchi M., Konno Y., Watari H., Sudo S., Sakuragi N., Emerging therapeutic biomarkers in endometrial cancer. BioMed Research International 2013 2013 11 130362 10.1155/2013/130362
5. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I., Endometrial cancer. The Lancet 2005 366 9484 491 505 2-s2.0-23444461364 10.1016/S0140-6736(05)67063-8 (Pubitemid 41111699)
6. Tsujikawa T., Yoshida Y., Kudo T., Kiyono Y., Kurokawa T., Kobayashi M., Tsuchida T., Fujibayashi Y., Kotsuji F., Okazawa H., Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET. Journal of Nuclear Medicine 2009 50 10 1598 1604 2-s2.0-70349647608 10.2967/jnumed.108.060145
7. Saarelainen S. K., Kööbi L., Järvenpää R., Laurila M., Mäenpää J. U., The preoperative assessment of deep myometrial invasion by three-dimensional ultrasound versus MRI in endometrial carcinoma. Acta Obstetricia et Gynecologica Scandinavica 2012 91 8 983 990 10.1111/j.1600-0412.2012.01439.x
8. Perzyło K., Miotła P., Lis E., Rechberger T., Therapeutic and prognostic value of lymphadenectomy in gynecological oncology. Ginekologia Polska 2013 84 7 630 636
9. Bhartiya D., Unni S., Parte S., Anand S., Very small embryonic-like stem cells: implications in reproductive biology. BioMed Research International 2013 2013 10 682326 10.1155/2013/682326
10. Çetin C., Özdemir S., Esen H., Balc O., Yilmaz O., The clinical value of preoperative and intraoperative assessments in the management of endometrial cancer. International Journal of Gynecological Cancer 2010 20 3 358 362 2-s2.0-77952112361 10.1111/IGC.0b013e3181cff1f3
11. Koolen B. B., Vrancken Peeters M. J., Wesseling J., Lips E. H., Vogel W. V., Aukema T. S., van Werkhoven E., Gilhuijs K. G., Rodenhuis S., Rutgers E. J., Valdés Olmos R. A., Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging 2012 39 12 1830 1838
12. Singh D., Miles K., Multiparametric PET/CT in oncology. Cancer Imaging 2012 12 2 336 344
13. Gilardi L., De Cicco C., Paganelli G., Preoperative FDG PET/CT in breast cancer patients: where are we going? European Journal of Nuclear Medicine and Molecular Imaging 2012 39 11 1667 1669
14. Quick C. M., May T., Horowitz N. S., Nucci M. R., Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. International Journal of Gynecological Pathology 2012 31 4 337 343 10.1097/PGP.0b013e31823ff422
15. Hidaka T., Kato K., Yonezawa R., Shima T., Nakashima A., Nagira K., Nakamura T., Saito S., Omission of lymphadenectomy is possible for low-risk corpus cancer. European Journal of Surgical Oncology 2007 33 1 86 90 2-s2.0-33846386839 10.1016/j.ejso.2006.09.035 (Pubitemid 46131875)
16. Paulino A. C., Johnstone P. A. S., FDG-PET in radiotherapy treatment planning: pandora's box? International Journal of Radiation Oncology Biology Physics 2004 59 1 4 5 2-s2.0-16344364167 10.1016/j.ijrobp.2003.10.045 (Pubitemid 38501500)
17. Fukui M. B., Blodgett T. M., Snyderman C. H., Johnson J. J., Myers E. N., Townsend D. W., Meltzer C. C., Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 2005 25 4 913 930 2-s2.0-23944512166 (Pubitemid 41196929)
18. Hickeson M., Yun M., Matthies A., Zhuang H., Adam L.-E., Lacorte L., Alavi A., Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. European Journal of Nuclear Medicine 2002 29 12 1639 1647 2-s2.0-0036454017 10.1007/s00259-002-0924-0
19. Koolen B. B., Vrancken Peeters M. J., Wesseling J., Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging 2012 39 12
20. Nakamura K., Kodama J., Okumura Y., Hongo A., Kanazawa S., Hiramatsu Y., The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer. International Journal of Gynecological Cancer 2010 20 1 110 115 2-s2.0-74249114553 10.1111/IGC.0b013e3181c3a288
21. Nakamura K., Hongo A., Kodama J., Hiramatsu Y., The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer. Gynecologic Oncology 2011 123 1 82 87 2-s2.0-80052572656 10.1016/j.ygyno.2011.06.026
22. Lee H. J., Ahn B.-C., Hong C. M., Song B. I., Kim H. W., Kang S., Jeong S. Y., Lee S.-W., Lee J., Preoperative risk stratification using18F-FDG PET/CT in women with endometrial cancer. NuklearMedizin 2011 50 5 204 213 2-s2.0-80053504612 10.3413/nukmed-0375-10-12
23. Torizuka T., Nakamura F., Takekuma M., Kanno T., Ogusu T., Yoshikawa E., Okada H., Maeda M., Ouchi Y., FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nuclear Medicine Communications 2006 27 6 481 487 2-s2.0-33746430148 10.1097/00006231-200606000- 00002 (Pubitemid 44309708)
24. 18F]FDG PET/CT in endometrial cancer. European Journal of Nuclear Medicine and Molecular Imaging 2012 1 6 2-s2.0-84857006923 10.1007/s00259-011- 2057-9
25. Nakamura K., Joja I., Fukushima C., Haruma T., Hayashi C., Kusumoto T., Seki N., Hongo A., Hiramatsu Y., The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 1 52 60
26. Kasper B., Dimitrakopoulou-Strauss A., Pilz L. R., Strauss L. G., Sachpekidis C., Hohenberger P., Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib. BioMed Research International 2013 2013 7 389672 10.1155/2013/389672.